The potential role of glycogen metabolism in diffuse large B-cell lymphoma

References

• Adeva-Andany MM, González-Lucán M, Donapetry-García C, et al. Glycogen metabolism in humans. BBA Clin. 2016;5:85–100.
   PubMed Web of Science ®Google Scholar
• Dashty M. A quick look at biochemistry: carbohydrate metabolism. Clin Biochem. 2013;46(15):1339–1352.
   PubMed Web of Science ®Google Scholar
• Kanungo S, Wells K, Tribett T, et al. Glycogen metabolism and glycogen storage disorders. Ann Transl Med. 2018;6(24):474.
   PubMed Web of Science ®Google Scholar
• Prats C, Graham TE, Shearer J. The dynamic life of the glycogen granule. J Biol Chem. 2018;293(19):7089–7098.
   PubMed Web of Science ®Google Scholar
• Roach PJ, Depaoli-Roach AA, Hurley TD, et al. Glycogen and its metabolism: some new developments and old themes. Biochem J. 2012;441(3):763–787.
   PubMedGoogle Scholar
• Deng D, Yan N. GLUT, SGLT, and SWEET: structural and mechanistic investigations of the glucose transporters. Protein Sci. 2016;25(3):546–558.
   PubMed Web of Science ®Google Scholar
• John S, Weiss JN, Ribalet B. Subcellular localization of hexokinases I and II directs the metabolic fate of glucose. PLoS One. 2011;6(3):e17674.
   PubMed Web of Science ®Google Scholar
• Wilson JE. Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J Exp Biol. 2003;206(12):2049–2057.
   PubMed Web of Science ®Google Scholar
• Beurel E, Grieco SF, Jope RS. Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol Ther. 2015;148:114–131.
   PubMed Web of Science ®Google Scholar
• McCubrey JA, Steelman LS, Bertrand FE, et al. Multifaceted roles of GSK-3 and Wnt/beta-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention. Leukemia. 2014;28(1):15–33.
   PubMed Web of Science ®Google Scholar
• Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–314.
   PubMed Web of Science ®Google Scholar
• Warburg O. On respiratory impairment in cancer cells. Science. 1956;124(3215):269–270.
   PubMed Web of Science ®Google Scholar
• Fu Y, et al. The reverse Warburg effect is likely to be an Achilles’ heel of cancer that can be exploited for cancer therapy. Oncotarget. 2017;8(34):57813–57825.
   PubMedGoogle Scholar
• Zheng J. Energy metabolism of cancer: glycolysis versus oxidative phosphorylation (Review). Oncol Lett. 2012;4(6):1151–1157.
   PubMed Web of Science ®Google Scholar
• Shulman RG, Rothman DL. The glycogen shunt maintains glycolytic homeostasis and the warburg effect in cancer. Trends Cancer. 2017;3(11):761–767.
   PubMed Web of Science ®Google Scholar
• Shulman RG, Rothman DL. Homeostasis and the glycogen shunt explains aerobic ethanol production in yeast. Proc Natl Acad Sci Usa. 2015;112(35):10902–10907.
   PubMed Web of Science ®Google Scholar
• Rousset M, Zweibaum A, Fogh J. Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins. Cancer Res. 1981;41(3):1165–1170.
   PubMed Web of Science ®Google Scholar
• Sato A, Kawasaki T, Kashiwaba M, et al. Glycogen-rich clear cell carcinoma of the breast showing carcinomatous lymphangiosis and extremely aggressive clinical behavior. Pathol Int. 2015;65(12):674–676.
   PubMed Web of Science ®Google Scholar
• Pelletier J, Bellot G, Gounon P, et al. Glycogen synthesis is induced in hypoxia by the hypoxia-inducible factor and promotes cancer cell survival. Front Oncol. 2012;2:18.
   PubMedGoogle Scholar
• Pescador N, Villar D, Cifuentes D, et al. Hypoxia promotes glycogen accumulation through hypoxia inducible factor (HIF)-mediated induction of glycogen synthase 1. PLoS One. 2010;5(3):e9644.
   PubMed Web of Science ®Google Scholar
• Favaro E, Bensaad K, Chong MG, et al. Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells. Cell Metab. 2012;16(6):751–764.
   PubMed Web of Science ®Google Scholar
• Zois CE, Harris AL. Glycogen metabolism has a key role in the cancer microenvironment and provides new targets for cancer therapy. J Mol Med. 2016;94(2):137–154.
   PubMed Web of Science ®Google Scholar
• Dejure FR, Eilers M. MYC and tumor metabolism: chicken and egg. Embo J. 2017;36(23):3409–3420.
   PubMed Web of Science ®Google Scholar
• Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer. 2008;8(12):976–990.
   PubMed Web of Science ®Google Scholar
• Valera A, Pujol A, Gregori X, et al. Evidence from transgenic mice that myc regulates hepatic glycolysis. Faseb J. 1995;9(11):1067–1078.
   PubMed Web of Science ®Google Scholar
• Gordan JD, Thompson CB, Simon MC. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell. 2007;12(2):108–113.
   PubMed Web of Science ®Google Scholar
• Domoto T, Pyko IV, Furuta T, et al. Glycogen synthase kinase-3beta is a pivotal mediator of cancer invasion and resistance to therapy. Cancer Sci. 2016;107(10):1363–1372.
   PubMed Web of Science ®Google Scholar
• Wu X, Stenson M, Abeykoon J, et al. Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma. Blood. 2019;134(4):363.
   PubMed Web of Science ®Google Scholar
• Varano G, Raffel S, Sormani M, et al. The B-cell receptor controls fitness of MYC-driven lymphoma cells via GSK3beta inhibition. Nature. 2017;546(7657):302–306.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–511.
   PubMed Web of Science ®Google Scholar
• Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019;94(5):604–616.
   PubMed Web of Science ®Google Scholar
• Skrabek P, Assouline S, Christofides A, et al. Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma. Curr Oncol. 2019;26(4):253–265.
   PubMed Web of Science ®Google Scholar
• Monti S. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood. 2005;105(5):1851–1861.
   PubMed Web of Science ®Google Scholar
• Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–1808.
   PubMed Web of Science ®Google Scholar
• Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2011;2011(1):498–505.
   PubMed Web of Science ®Google Scholar
• Schoder H, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23(21):4643–4651.
   PubMed Web of Science ®Google Scholar
• Elstrom R, Guan L, Baker G, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood. 2003;101(10):3875–3876.
   PubMed Web of Science ®Google Scholar
• Hirose Y, Suefuji H, Kaida H, et al. Relationship between 2-deoxy-2-[(18)F]-fluoro-d-glucose uptake and clinicopathological factors in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2014;55(3):520–525.
   PubMed Web of Science ®Google Scholar
• Shim HK, Lee WW, Park SY, et al. Expressions of glucose transporter Types 1 and 3 and hexokinase-II in diffuse large B-cell lymphoma and other B-cell non-Hodgkin’s lymphomas. Nucl Med Biol. 2009;36(2):191–197.
   PubMed Web of Science ®Google Scholar
• Wu X, Pertovaara H, Korkola P, et al. Glucose metabolism correlated with cellular proliferation in diffuse large B-cell lymphoma. Leuk Lymphoma. 2012;53(3):400–405.
   PubMed Web of Science ®Google Scholar
• Soleja M, Mims M, Rivero G. Uncovering molecular abnormalities leading to the Warburg effect in primary refractory diffuse large B-cell lymphoma. Blood Cancer J. 2016;6(12):e502.
   PubMedGoogle Scholar
• Elhomsy GC, Eranki V, Albert SG, et al. “Hyper-warburgism,” a cause of asymptomatic hypoglycemia with lactic acidosis in a patient with non-Hodgkin’s lymphoma. J Clin Endocrinol Metab. 2012;97(12):4311–4316.
   PubMed Web of Science ®Google Scholar
• Mason EF, Zhao Y, Goraksha-Hicks P, et al. Aerobic glycolysis suppresses p53 activity to provide selective protection from apoptosis upon loss of growth signals or inhibition of BCR-Abl. Cancer Res. 2010;70(20):8066–8076.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Altman BJ, Coloff JL, et al. Glycogen synthase kinase 3alpha and 3beta mediate a glucose-sensitive antiapoptotic signaling pathway to stabilize Mcl-1. Mol Cell Biol. 2007;27(12):4328–4339.
   PubMed Web of Science ®Google Scholar
• Coloff JL, Macintyre AN, Nichols AG, et al. Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition. Cancer Res. 2011;71(15):5204–5213.
   PubMed Web of Science ®Google Scholar
• Bhalla K, Jaber S, Nahid M N, et al. Role of hypoxia in diffuse large B-cell lymphoma: metabolic repression and selective translation of HK2 facilitates development of DLBCL. Sci Rep. 2018;8(1):744.
   PubMedGoogle Scholar
• Gu JJ, Singh A, Xue K, et al. Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development. Oncotarget. 2018;9(3):4020–4033.
   PubMedGoogle Scholar
• Galluzzi L, Kepp O, Tajeddine N, et al. Disruption of the hexokinase-VDAC complex for tumor therapy. Oncogene. 2008;27(34):4633–4635.
   PubMed Web of Science ®Google Scholar
• Pedersen PL. Warburg, me and hexokinase 2: multiple discoveries of key molecular events underlying one of cancers’ most common phenotypes, the “Warburg Effect”, i.e., elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr. 2007;39(3):211–222.
   PubMed Web of Science ®Google Scholar
• Fornecker L-M, Muller L, Bertrand F, et al. Multi-omics dataset to decipher the complexity of drug resistance in diffuse large B-cell lymphoma. Sci Rep. 2019;9(1):895.
   PubMedGoogle Scholar
• Wyatt E, Wu R, Rabeh W, et al. Regulation and cytoprotective role of hexokinase III. PLoS One. 2010;5(11):e13823.
   PubMed Web of Science ®Google Scholar
• Jacquin MA, Chiche J, Zunino B, et al. GAPDH binds to active Akt, leading to Bcl-xL increase and escape from caspase-independent cell death. Cell Death Differ. 2013;20(8):1043–1054.
   PubMed Web of Science ®Google Scholar
• Chiche J, Pommier S, Beneteau M, et al. GAPDH enhances the aggressiveness and the vascularization of non-Hodgkin’s B lymphomas via NF-kappaB-dependent induction of HIF-1alpha. Leukemia. 2015;29(5):1163–1176.
   PubMed Web of Science ®Google Scholar
• Chiche J, Reverso-Meinietti J, Mouchotte A, et al. GAPDH expression predicts the response to R-CHOP, the tumor metabolic status, and the response of DLBCL patients to metabolic inhibitors. Cell Metabolism. 2019;29(6):1243–1257 e10.
   PubMed Web of Science ®Google Scholar
• Bromberg J, Darnell JE. Jr., The role of STATs in transcriptional control and their impact on cellular function. Oncogene. 2000;19(21):2468–2473.
   PubMed Web of Science ®Google Scholar
• Wu ZL, Song YQ, Shi YF, et al. High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma. J Hematol Oncol. 2011;4(1):31.
   PubMedGoogle Scholar
• Ding BB, Yu JJ, Yu RY-L, et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood. 2008;111(3):1515–1523.
   PubMed Web of Science ®Google Scholar
• Huang X, Meng B, Iqbal J, et al. Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2013;31(36):4520–4528.
   PubMed Web of Science ®Google Scholar
• Demaria M, Giorgi C, Lebiedzinska M, et al. A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction. Aging. 2010;2(11):823–842.
   PubMedGoogle Scholar
• Uddin S, Hussain AR, Siraj AK, et al. Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood. 2006;108(13):4178–4186.
   PubMed Web of Science ®Google Scholar
• Yin H, Zhong F, Ouyang Y, et al. Upregulation of ADAM12 contributes to accelerated cell proliferation and cell adhesion-mediated drug resistance (CAM-DR) in Non-Hodgkin’s Lymphoma. Hematology. 2017;22(9):527–535.
   PubMed Web of Science ®Google Scholar
• Sasi BK, Martines C, Xerxa E, et al. Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma. Leukemia. 2019;33(10):2416.
   PubMed Web of Science ®Google Scholar
• Karmali R, Chukkapalli V, Gordon LI, et al. GSK-3beta inhibitor, 9-ING-41, reduces cell viability and halts proliferation of B-cell lymphoma cell lines as a single agent and in combination with novel agents. Oncotarget. 2017;8(70):114924–114934.
   PubMedGoogle Scholar
• Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013;121(20):4021–4031. quiz 4250.
   PubMed Web of Science ®Google Scholar